受强制性开放获取政策约束的文章 - Rohan Paul了解详情
可在其他位置公开访问的文章：3 篇
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, N Staplin, KJ Mayne, C Wanner, JB Green, SJ Hauske, ...
The Lancet Diabetes & Endocrinology 12 (1), 51-60, 2024
强制性开放获取政策： US National Institutes of Health, British Heart Foundation, UK Medical …
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
N Staplin, R Haynes, PK Judge, C Wanner, JB Green, J Emberson, ...
The Lancet Diabetes & Endocrinology 12 (1), 39-50, 2024
强制性开放获取政策： British Heart Foundation, UK Medical Research Council, National Institute …
Bone marrow from focal segmental glomerulosclerosis displays activation of inflammatory pathway
P Rashmi, P Boada, A Soni, TK Sigdel, D Rychkov, E Hahm, AA Da Silva, ...
medRxiv, 2023.03. 06.23286859, 2023
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定